[go: up one dir, main page]

AR024600A1 - PREPARATION OF CYCLOPENTANE AND CYCLOPENTENE COMPOUNDS SUBSTITUTED AND CERTAIN INTERMEDIARIES - Google Patents

PREPARATION OF CYCLOPENTANE AND CYCLOPENTENE COMPOUNDS SUBSTITUTED AND CERTAIN INTERMEDIARIES

Info

Publication number
AR024600A1
AR024600A1 ARP000103274A ARP000103274A AR024600A1 AR 024600 A1 AR024600 A1 AR 024600A1 AR P000103274 A ARP000103274 A AR P000103274A AR P000103274 A ARP000103274 A AR P000103274A AR 024600 A1 AR024600 A1 AR 024600A1
Authority
AR
Argentina
Prior art keywords
formula
compound
substituted
cyclopentane
isoxazoline
Prior art date
Application number
ARP000103274A
Other languages
Spanish (es)
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of AR024600A1 publication Critical patent/AR024600A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00Preparation of halogenated hydrocarbons
    • C07C17/093Preparation of halogenated hydrocarbons by replacement by halogens
    • C07C17/10Preparation of halogenated hydrocarbons by replacement by halogens of hydrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/16Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of rings other than six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24Y being a hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compuestos de ciclopentano y ciclopenteno sustituidos que son utiles como inhibidores de la neuraminidasa representados por las siguientes formulas (1) y(2), donde cada R1 es individualmente alquilo o alquilo sustituido, alquenilo o alquenilo sustituido de 1-6 átomos de carbono, o H; cada uno de R2 y R3 esindividualmente alquilo o alquenilo de 1-8 átomos de carbono, cicloalquilo o cicloalquilo sustituido de 4-8 átomos de carbono, arilo o arilo sustituido,arilalquilo o arilalquilo sustituido,o Hcon la condicion de que por lo menos uno de R2 y R3 sea otro que H;X es NHR1, NHC (=NH) NHR4 donde R4 es H, alquilo de1-6 átomos de carbono, OR1, COR1, COOR1, CN o NO2; A es H, F, OR1, OCOR1, -OOCNHR1, NHR1, o NHCOOR1; y sales aceptables para uso farmacéutico de los mismos. Esposible preparar los compuestos de formula (1) donde A es H a partir de derivados de isoxazolina novedosos representados por la formula (3), donde R2 y R3tienen los valores definidos anteriormente y donde cada uno de Y y Zes individualmente COOR1 o H con la condicion de que por lo menos uno de Y y Z sea otro queH. Los derivados de isoxazolina de acuerdo con la formula (3) se preparan de acuerdo con el siguiente procedimiento: Se hace reaccionar a un oxido de nitrilodela formula (4) con ciertos derivados de ciclopentano. Se puede preparar el compuesto ciclopentano de formula (1) a partir de los derivados de isoxazolina utsupra reduciendo los derivados de isoxazolina de formula (3) para formar un derivado aminoalcohol. Se hace reaccionar el compuesto aminoalcohol de formula (5)con un anhídrido o haluro ácido de un ácido carboxílico para dar un compuesto acilado. Después, el grupo alcohol del compuesto acilado se convierte en gruposaliente que a su vez es desplazado por amoníaco o guanidina para dar compuestos de formula (1) o se desplaza al grupo saliente con un ion azida que a su vezse convierte en la guanidina usando un compuesto NH2. En un proceso alternativo para preperar el compuesto ciclopentano deformula (1), se convierte en cetonaun compuesto isoxazolina de formula (3) abriendo su anillo isoxazolina Se somete a la cetona a una aminacion reductiva de la conversion al producto final comoSubstituted cyclopentane and cyclopentene compounds that are useful as neuraminidase inhibitors represented by the following formulas (1) and (2), where each R1 is individually substituted alkyl or alkyl, alkenyl or substituted alkenyl of 1-6 carbon atoms, or H; each of R2 and R3 is individually alkyl or alkenyl of 1-8 carbon atoms, cycloalkyl or substituted cycloalkyl of 4-8 carbon atoms, aryl or substituted aryl, arylalkyl or substituted arylalkyl, or H with the proviso that at least one of R2 and R3 is other than H; X is NHR1, NHC (= NH) NHR4 where R4 is H, alkyl of 1-6 carbon atoms, OR1, COR1, COOR1, CN or NO2; A is H, F, OR1, OCOR1, -OOCNHR1, NHR1, or NHCOOR1; and salts acceptable for pharmaceutical use thereof. It is possible to prepare the compounds of formula (1) where A is H from novel isoxazoline derivatives represented by formula (3), where R2 and R3 have the values defined above and where each of Y and Z individually COOR1 or H with the condition that at least one of Y and Z is another queH. The isoxazoline derivatives according to the formula (3) are prepared according to the following procedure: The nitrile oxide formula (4) is reacted with certain cyclopentane derivatives. The cyclopentane compound of formula (1) can be prepared from the isoxazoline derivatives utsupra by reducing the isoxazoline derivatives of formula (3) to form an amino alcohol derivative. The amino alcohol compound of formula (5) is reacted with an acid anhydride or halide of a carboxylic acid to give an acylated compound. Then, the alcohol group of the acylated compound is converted into a salient group which in turn is displaced by ammonia or guanidine to give compounds of formula (1) or is displaced to the leaving group with an azide ion which in turn is converted into guanidine using a NH2 compound. In an alternative process to prepare the cyclopentane deformula compound (1), it is converted into ketone or an isoxazoline compound of formula (3) by opening its isoxazoline ring. The ketone is subjected to a reductive amination of the conversion to the final product as

ARP000103274A 1999-06-28 2000-06-28 PREPARATION OF CYCLOPENTANE AND CYCLOPENTENE COMPOUNDS SUBSTITUTED AND CERTAIN INTERMEDIARIES AR024600A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14084099P 1999-06-28 1999-06-28

Publications (1)

Publication Number Publication Date
AR024600A1 true AR024600A1 (en) 2002-10-16

Family

ID=22493015

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000103274A AR024600A1 (en) 1999-06-28 2000-06-28 PREPARATION OF CYCLOPENTANE AND CYCLOPENTENE COMPOUNDS SUBSTITUTED AND CERTAIN INTERMEDIARIES

Country Status (6)

Country Link
EP (1) EP1189862A1 (en)
JP (1) JP2003530306A (en)
AR (1) AR024600A1 (en)
AU (1) AU6056600A (en)
CA (1) CA2377287A1 (en)
WO (1) WO2001000558A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062242A1 (en) * 2000-02-24 2001-08-30 Biocryst Pharmaceuticals, Inc. Prodrugs of substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
WO2002092555A1 (en) * 2001-05-11 2002-11-21 Sankyo Company, Limited Sialic acid derivatives
CN101367750B (en) * 2007-08-14 2012-05-23 中国人民解放军军事医学科学院毒物药物研究所 (1S,2S,3S,4R)-3-[(1S)-1-acet-ammonia-2-ethyl-butyl]-4- guanidino-2-hydroxyl-cyclopentyl-1-carboxylic acid aqua compound and medical uses thereof
CN102584637B (en) * 2011-01-17 2014-07-09 天津药物研究院 Peramivir hydrate crystal, preparation method, medical compound and usage thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR016162A1 (en) * 1997-12-17 2001-06-20 Biocryst Pharm Inc SUBSTITUTED CYCLOPENTANE AND CYCLOPENTENE COMPOUNDS THAT ARE USEFUL AS INHIBITORS OF NEURAMINIDASE AND COMPOSITION THAT CONTAINS THEM.

Also Published As

Publication number Publication date
WO2001000558A1 (en) 2001-01-04
JP2003530306A (en) 2003-10-14
EP1189862A1 (en) 2002-03-27
CA2377287A1 (en) 2001-01-04
AU6056600A (en) 2001-01-31

Similar Documents

Publication Publication Date Title
AR032679A1 (en) DERIVATIVES OF THE ISOFTALIC ACID AS INHIBITORS OF METALOPROTEINASES OF THE MATRIX
BRPI0511186A (en) compound, compound prodrug, pharmaceutical composition, use of compound, and process for preparing compound
HUP0100142A2 (en) Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
UY27039A1 (en) FORMS OF ACID AMIDA SALT 3- (4-BROMO-2,6-DIFLUORO-BENCILOXI) -5- (3- (PIRROLIDIN-1-ILBUTIL) UREIDO) ISOTIAZOL-4-CARBOXILICO AND PRODUCTION METHODS
BRPI0313477B8 (en) purine derivatives, pharmaceutical composition comprising them, their preparation process and use
BR0313545A (en) Process for the preparation of 4 - [[4 - [[4- (2-cyanoethenyl) -2,6-dimethylphenyl] amino] -2-pyrimidinyl] amino] benzonitrile
ES2186251T3 (en) NEW DERIVATIVES OF ACILGUANIDINE AS INHIBITORS OF BONE RESORTION AND AS AN ANTIGONISTS OF VITRONECTINE RECEPTORS.
BRPI0008753B8 (en) amide compound, process for preparing an amide compound, pharmaceutical composition and use of an amide compound
GB1063749A (en) New guanidine derivatives and processes for their production
PE20070007A1 (en) METHODS FOR SYNTHESIZING 6-ALKYLAMINOQUINOLINE DERIVATIVES
AR024600A1 (en) PREPARATION OF CYCLOPENTANE AND CYCLOPENTENE COMPOUNDS SUBSTITUTED AND CERTAIN INTERMEDIARIES
DE602006009619D1 (en) PROCESS FOR PREPARING 1-AMINO-3,5-DIMETHYLADAMANTANE HYDROCHLORIDE
GB853799A (en) Diquaternary compounds and process of preparing same
ATE413391T1 (en) METHOD FOR PRODUCING N-1 PROTECTED RING-NITROGEN-CONTAINING CYCLIC POLYAMINES AND COMPOUNDS THEREOF
NO20073549L (en) Process for the preparation of organic compounds
NO975679L (en) Process for Preparation of N-Monosubstituted and N, N'-Disubstituted Unsymmetrical Cyclic Urea
AR057451A1 (en) METHODS TO PREPARE DERIVATIVES OF GLUTAMIC ACID
BR9606429A (en) Compound composition and process for treatment of dysfunction mediated by uPar- or uPa-
ATE159521T1 (en) THIOACYLATING AGENTS AND INTERMEDIATE PRODUCTS, THIOPEPTIDES, AND METHOD FOR THE PRODUCTION AND USE THEREOF
KR910011893A (en) Heterocyclic Aminodiol β-Amino Acid Derivatives
KR960029312A (en) N-arylalkylphenylacetamide derivatives and preparation methods thereof
AR045727A1 (en) FLUOROCOMBRETASTATINA AND DERIVATIVES OF THE SAME
AR044341A1 (en) PROCESS FOR SYNTHESIS OF INTERMEDIARIES OF BETALACTAMASA INHIBITORS
ES340298A1 (en) Hydantoins and processes for the preparation thereof
BRPI0519327A2 (en) unsubstituted salicylamide preparation process, compound, use thereof and pharmaceutical composition